Drug Res (Stuttg) 2015; 65(S 01): S13
DOI: 10.1055/s-0035-1558063
Symposium der Paul-Martini-Stiftung
Georg Thieme Verlag KG Stuttgart · New York

Development of a Disease-Modifying OA Drug (DMOAD) in Knee Osteoarthritis: The Example of Sprifermin

K. Marhardt*
1   Merck Gesellschaft mbH, Vienna, Austria
,
N. Muurahainen*
2   EMD Serono, Rockland/MA, USA
› Author Affiliations
Further Information

Publication History

Publication Date:
04 November 2015 (online)

  1. Introduction: OA and unmet clinical need for a DMOAD

  2. Past DMOAD drug development

  3. Sprifermin, its MOA, and clinical development program

  4. Lessons learned, summary, and next steps

* both are affiliates of Merck KGaA, Darmstadt, Germany


 
  • References

  • 1 Hellio Le Graverand MP, Clemmer RS, Redifer P et al. A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee. Ann Rheum Dis 2013; 72: 187-195
  • 2 Reginster JY, Badurski J, Bellamy N et al. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Ann Rheum Dis 2013; 72: 179-186
  • 3 Karsdal MA, Byrjalsen I, Alexandersen P et al. Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials. Osteoarthritis Cartilage 2015; 23: 532-543
  • 4 Brandt KD, Mazzuca SA. Lessons learned from nine clinical trails of disease modifying osteoarthritis drugs. Arthritis & Rheumatism 2005; 52: 3349-3359